<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637633</url>
  </required_header>
  <id_info>
    <org_study_id>Farwanyia Hospital</org_study_id>
    <nct_id>NCT04637633</nct_id>
  </id_info>
  <brief_title>Topical Cyclosporine-A for Management of Epiphora</brief_title>
  <acronym>CSA-epiphora</acronym>
  <official_title>Topical Cyclosporine-A for Management of Epiphora in Eyes With Acquired Punctal Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farwaniya Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Farwaniya Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating&#xD;
      epiphora in eyes with acquired punctum stenosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a prospective study included patients who were referred to our outpatient clinics in&#xD;
      Farwanyia hospital, Kuwait during the period between July 2019 and January 2020, having&#xD;
      symptomatic epiphora associated with severe acquired lower punctal stenosis. Patients were&#xD;
      treated with topical 0.05% CsA on twice daily dose with topical preservative free artificial&#xD;
      tears Q.I. D. Patients were followed up monthly for at least 3 months by epiphora grading,&#xD;
      Fluorescein dye disappearance test (FDT) and evaluating the patient satisfaction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epiphora grading</measure>
    <time_frame>3 months</time_frame>
    <description>Munk grading system score from 0 to 5 the higher the worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluorescein dye disappearance test (FDT)</measure>
    <time_frame>3 months</time_frame>
    <description>via installing a drop of 2% fluorescein and asses the height of the tear film in millimeters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Epiphora</condition>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,</intervention_name>
    <description>topical preservative free artificial tears Q.I. D.</description>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <other_name>preservative free artificial tears</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients of either sex&#xD;
&#xD;
          -  had a diagnosis of epiphora that persisted more than three months both indoors and&#xD;
             outdoors&#xD;
&#xD;
          -  grade 0 punctal stenosis&#xD;
&#xD;
          -  did not adequately respond to artificial tears, topical corticosteroids and topical&#xD;
             antibiotics or in whom corticosteroids were discontinued due to their side effects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  congenital punctal obstruction&#xD;
&#xD;
          -  edematous puncti&#xD;
&#xD;
          -  allergic conjunctivitis&#xD;
&#xD;
          -  history of dacryocystitis,&#xD;
&#xD;
          -  inflammatory systemic diseases&#xD;
&#xD;
          -  any previous chemotherapy treatment, and local irradiation.&#xD;
&#xD;
          -  other causes of epiphora, lid laxity, entropion, and ectropion&#xD;
&#xD;
          -  lid malposition, canalicular or nasolacrimal sac or duct obstruction&#xD;
&#xD;
          -  previous eyelid or lacrimal drainage surgery&#xD;
&#xD;
          -  untreated conjunctivitis or blepharitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Farwanyia Hospital</name>
      <address>
        <city>Kuwait</city>
        <state>Farwanyia</state>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kuwait</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Farwaniya Hospital</investigator_affiliation>
    <investigator_full_name>Mona A Nassief</investigator_full_name>
    <investigator_title>lecturer of ophthalmology Mansoura University Egypt currentlty working as senior registrar in Farwaniya Hospital</investigator_title>
  </responsible_party>
  <keyword>cyclosporine A</keyword>
  <keyword>Epiphora</keyword>
  <keyword>punctal stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacrimal Apparatus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

